<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500251</url>
  </required_header>
  <id_info>
    <org_study_id>Belimumab</org_study_id>
    <nct_id>NCT02500251</nct_id>
  </id_info>
  <brief_title>Belimumab Impacting Transplant Eligibility</brief_title>
  <official_title>Belimumab-Based Plasma Cell Targeted Therapy to Impact Transplant Eligibility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>E. Steve Woodle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, open label, phase I/II pilot study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, open label, phase I/II pilot study. For Treatment Groups A and&#xD;
      B, the duration of study will include a 5 month enrollment period and approximately 7 months&#xD;
      of follow-up. For Treatment Group C, the duration of study will include a 3 month enrollment&#xD;
      period and approximately 7 months of follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of belimumab as measured by percent reduction in iDSA and/or iAb</measure>
    <time_frame>7 months</time_frame>
    <description>Maximal percent reduction in immunodominant DSA (iDSA) [highest titer DSA (MFI)] and/or immunodominant antibody (iAb) from pre-treatment to Day 151.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of belimumab as measured by toxicities and peripheral neuropathy</measure>
    <time_frame>7 months</time_frame>
    <description>Overall safety of belimumab when used in the desensitization setting with bortezomib with or without rituximab (Incidence of grade 3 and above non-hematologic toxicities; Incidence of grade 4 hematologic toxicities; Incidence of all grades of peripheral neuropathy)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Renal Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Group A (5 subjects)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive bortezomib and plasmapheresis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (5 subjects)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive belimumab, bortezomib, and plasmapheresis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (5 subjects)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive belimumab, bortezomib, rituximab, and plasmapheresis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>belimumab</intervention_name>
    <description>Belimumab will be administered per study protocol.</description>
    <arm_group_label>Group B (5 subjects)</arm_group_label>
    <arm_group_label>Group C (5 subjects)</arm_group_label>
    <other_name>benlysta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib will be administered per study protocol.</description>
    <arm_group_label>Group A (5 subjects)</arm_group_label>
    <arm_group_label>Group B (5 subjects)</arm_group_label>
    <arm_group_label>Group C (5 subjects)</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab will be administered per study protocol.</description>
    <arm_group_label>Group C (5 subjects)</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plasmapheresis</intervention_name>
    <description>Plasmapheresis will be administered per study protocol.</description>
    <arm_group_label>Group A (5 subjects)</arm_group_label>
    <arm_group_label>Group B (5 subjects)</arm_group_label>
    <arm_group_label>Group C (5 subjects)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is between 18 and 65 years of age, inclusive, with end-stage renal disease&#xD;
             awaiting kidney transplantation.&#xD;
&#xD;
          2. Patient with eligible living donor will have: DSA against living donor of &gt; 5,000 MFI&#xD;
             or a positive T or B cell flow cytometry crossmatch.&#xD;
&#xD;
          3. Patient that is on the kidney transplant waiting list awaiting a deceased donor&#xD;
             transplant and has an iAb of &gt; 8,000 MFI or has a current or peak calculated panel&#xD;
             reactive antibody (cPRA) &gt;20%.&#xD;
&#xD;
          4. Voluntary written informed consent before performance of any study-related procedure&#xD;
             not part of normal medical care, with the understanding that consent may be withdrawn&#xD;
             by the subject at any time without prejudice to future medical care.&#xD;
&#xD;
          5. Female subject is either post-menopausal for one year prior to screening or surgically&#xD;
             sterilized. Women of childbearing potential (WOCBP) must not become pregnant and so&#xD;
             must be sexually inactive by abstinence (starting 2 weeks prior to the 1st belimumab&#xD;
             and/or bortezomib dose) or use contraceptive methods with a failure rate of &lt; 1%&#xD;
             (starting 1 month prior to the 1st belimumab and/or bortezomib dose) for the duration&#xD;
             of the study through 16 weeks after the last belimumab and/or bortezomib dose. WOCBP&#xD;
             must have a negative urine or serum pregnancy test at screening and &lt; 7 days prior to&#xD;
             the first belimumab and/or bortezomib dose.&#xD;
&#xD;
          6. Male subjects, even if surgically sterilized (i.e., status post vasectomy) must agree&#xD;
             to 1 of the following: practice effective barrier contraception during the entire&#xD;
             study treatment period and through a minimum of 16 weeks after the last dose of&#xD;
             belimumab and/or bortezomib, or completely abstain from heterosexual intercourse.&#xD;
&#xD;
          7. Review of pre-transplant medical clearance by the patient's transplant nephrologist to&#xD;
             assure the patient is medically acceptable for study entry.&#xD;
&#xD;
          8. Cardiac evaluation by transplant nephrologist with clearance documented in writing to&#xD;
             participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Know hypersensitivity to bortezomib, boron or mannitol, rituximab, belimumab or any of&#xD;
             its components.&#xD;
&#xD;
          2. Have a history of an anaphylactic reaction to parenteral administration of contrast&#xD;
             agents, human or murine proteins or monoclonal antibodies.&#xD;
&#xD;
          3. Subjects judged by the investigator to be at significant risk of failing to comply&#xD;
             with the requirements of the protocol or unable to cooperate or communicate with the&#xD;
             investigator.&#xD;
&#xD;
          4. Abnormal ECG with clinically significant ventricular arrhythmias or other conduction&#xD;
             abnormality that in the opinion of the investigator warrants exclusion of the subject&#xD;
             from the trial.&#xD;
&#xD;
          5. Myocardial infarction within 6 months prior to enrollment or has New York Heart&#xD;
             Association (NYHA) Class III or IV heart failure (Appendix A), uncontrolled angina,&#xD;
             severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute&#xD;
             ischemia or active conduction system abnormalities. Prior to study entry, any&#xD;
             abnormality on ECG performed within 30 days of consent has to be documented by the&#xD;
             investigator or the patient's transplant nephrologist as not medically relevant.&#xD;
&#xD;
          6. Patient has Grade 2 peripheral neuropathy by CTCAE criteria within 14 days before&#xD;
             enrollment.&#xD;
&#xD;
          7. Patients with an absolute neutrophil count &lt; 1,000/mm3 or platelet count &lt; 75,000/mm3&#xD;
             within 30 days of consent.&#xD;
&#xD;
          8. Patient has received intravenous cyclophosphamide within 180 days prior to belimumab,&#xD;
             any biologic investigational agent within 365 days prior to belimumab, or any&#xD;
             non-biologic investigational agent within 30 days (or 5 half-lives, whichever is&#xD;
             greater) prior to belimumab.&#xD;
&#xD;
          9. Receipt of a live vaccine within 30 days prior to initiation of study treatment.&#xD;
&#xD;
         10. Received blood transfusions within 30 days prior to trial entry.&#xD;
&#xD;
         11. Have any intercurrent significant medical (other than renal disease) or psychiatric&#xD;
             illness that the investigator considers would make the candidate unsuitable for the&#xD;
             study.&#xD;
&#xD;
         12. Have a historically positive HIV test or test positive for HIV within one year of&#xD;
             consent.&#xD;
&#xD;
         13. Hepatitis status:&#xD;
&#xD;
             a. Hepatitis B: Serologic evidence of current or past Hepatitis B (HB) infection based&#xD;
             on the results of testing for HBsAg and anti-HBc as follows: i. Patients positive for&#xD;
             HBsAg or HBcAb historically or on testing performed within one year of consent are&#xD;
             excluded b. Hepatitis C: Positive test for Hepatitis C antibody with a detectable&#xD;
             viral load on testing performed within one year of consent.&#xD;
&#xD;
         14. History of malignancy within the past 5 years that is not considered to be cured, with&#xD;
             the exception of localized basal cell carcinoma of the skin (excised â‰¥ 2 years prior&#xD;
             to randomization).&#xD;
&#xD;
         15. Evidence of severe liver disease with abnormal liver profile (aspartate&#xD;
             aminotransferase (AST), alanine aminotransferase (ALT) or total bilirubin &gt; 1.5 times&#xD;
             upper limit of normal (ULN)) on testing performed within 30 days of consent.&#xD;
&#xD;
         16. Infection history: a)Currently on any suppressive therapy for a chronic infection&#xD;
             (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes&#xD;
             zoster and atypical mycobacteria). b) Hospitalization for treatment of infection&#xD;
             within 60 days of Day 0. c) Use of parenteral (IV or IM) antibiotics (antibacterials,&#xD;
             antivirals, anti-fungals, or anti parasitic agents) within 60 days of Day 0.&#xD;
&#xD;
         17. Pregnant or nursing (lactating) women and women who might become pregnant during the&#xD;
             study.&#xD;
&#xD;
         18. Have evidence of serious suicide risk including any history of suicidal behavior in&#xD;
             the last 6 months and/or any suicidal ideation in the last 2 months or who in the&#xD;
             investigator's judgment, pose a significant suicide risk.&#xD;
&#xD;
         19. Have a history of a primary immunodeficiency.&#xD;
&#xD;
         20. Have a significant IgG deficiency (IgG level &lt; 400 mg/dl) or have an IgA deficiency&#xD;
             (IgA level &lt; 10 mg/dL).&#xD;
&#xD;
         21. Have current drug or alcohol abuse or dependence, or a history of drug or alcohol&#xD;
             abuse or dependence within 364 days prior to Day 0.&#xD;
&#xD;
         22. Have any other clinically significant abnormal laboratory value in the opinion of the&#xD;
             investigator warrants exclusion of the subject from the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Steve Woodle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 9, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>April 19, 2019</last_update_submitted>
  <last_update_submitted_qc>April 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>E. Steve Woodle</investigator_full_name>
    <investigator_title>Director, Solid Organ Transplantation</investigator_title>
  </responsible_party>
  <keyword>Transplantation</keyword>
  <keyword>belimumab</keyword>
  <keyword>Velcade</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Belimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

